Promising results for drug candidate CS1

Jul 13

1 min read

This press release reports that over the 12 months of their Expanded Access Program enrolling ten patients, the majority of patients with pulmonary arterial hypertension who completed treatment with drug candidate CS1 maintained or improved their functional and biomarker status, and that CS1 showed a favourable safety and tolerability profile. A Phase IIb trial for CS1 begins this summer.

Read the Cereno Scientific press release

Recent Posts

Animal research shows miR-224 contributes to PAH

A small molecule called microRNA-224-5p (miR-224) appears to play an important role in the changes to the lung blood vessels that occur in pulmonary arterial hypertension (PAH). Researchers found that

Dual PH therapy before BPA lowers complications

Researchers found that pre-treating pulmonary hypertension (PH) patients with dual therapy before they underwent balloon pulmonary angioplasty was associated with lower complications and better clinic

Advances in subcutaneous infusion pump therapy for PAH

Infusion pump technology for subcutaneous prostacyclin analog therapy has improved, with improved user experiences, simplified priming processes, easier filling, capability for lower doses, and better

Comments